| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA. Supported by the Ross Mosier Fund.
Study objectives: (1) To determine the relationship between IgE levels and the prevalence of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) patients, (2) to establish the usefulness of assessing atopy as an identifying risk factor for ABPA, (3) to evaluate the clinical course of patients receiving and not receiving itraconazole as reflected in oral steroid dose requirements and number of acute episodes of ABPA, and (4) to determine the role of acute episodes of ABPA in pulmonary exacerbations of CF.
Design: Retrospective review of online clinical database and medical records.
Setting: CF clinic and inpatient services of Lucile Salter Packard Children's Hospital at Stanford.
Patients: One hundred seventy-two patients with CF for whom serial serum total IgE levels were measured over a 5-year study period, 1992 to 1996.
Interventions: We reviewed records of patients followed up at the CF Center at Stanford who had serum total IgE measured between January 1, 1992, and December 31, 1996. Total IgE and Aspergillus fumigatus (Af) specific IgE antibodies were measured by commercial fluorometric solid-phase immunoassay. Precipitating antibodies to Af were measured by double immunodiffusion. Patients who were diagnosed as having ABPA were treated with itraconazole unless significant liver dysfunction was present. Oral steroid dosing requirements and acute episodes of ABPA for days with vs days without itraconazole were compared.
Measurements and results: Serum total IgE was
elevated (> 1 SD > geometric mean for age) in 51% of patients
tested. IgE > 500 IU/mL, chosen as a screening cutoff for evaluating
possible ABPA, was present in 19% of patients at some time during the
study period. Atopy (defined as 
1 IU/mL IgE antibody to 1
allergen) was present in 61% of 104 patients tested for specific
allergen sensitization. ABPA was diagnosed in 16 patients (9%). ABPA
occurred in 22% of atopic CF patients but only in 2% of nonatopic
patients (p = 0.001). Six percent of pulmonary exacerbations
requiring hospitalization were associated with acute episodes of ABPA.
Over the study period, itraconazole use was associated with a reduced
average daily oral steroid dose of 47% (p = 0.05) and a reduction in
the number of acute ABPA episodes by 55% (p < 0.001).
Conclusions: Screening for atopy may be a cost-effective way to select CF patients for periodic monitoring with total serum IgE levels, since there is an increased risk of ABPA developing in atopic CF patients. Itraconazole treatment of ABPA is safe and associated with fewer acute episodes of ABPA despite reduction in average daily oral steroid dose.
Key Words: allergic bronchopulmonary aspergillosis • atopy • Aspergillus fumigatus • CFTR • corticosteroids • cystic fibrosis • genotype • IgE • itraconazole
This article has been cited by other articles:
|
|
 |
|
  D. Hartl, P. Latzin, G. Zissel, M. Krane, S. Krauss-Etschmann, and M. Griese Chemokines Indicate Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1370 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Conway, C. Etherington, D. G. Peckham, K. G. Brownlee, A. Whitehead, and H. Cunliffe Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis J. Antimicrob. Chemother., May 1, 2004; 53(5): 841 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Gibson, J. L. Burns, and B. W. Ramsey Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Nguyen The Gloved Finger Sign Radiology, May 1, 2003; 227(2): 453 - 454. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Skov, K.M. Main, I.B. Sillesen, J. Muller, C. Koch, and S. Lanng Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide Eur. Respir. J., July 1, 2002; 20(1): 127 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sermet-Gaudelus, A. Lesne-Hulin, G. Lenoir, E. Singlas, P. Berche, and C. Hennequin Sputum Itraconazole Concentrations in Cystic Fibrosis Patients Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1937 - 1938. [Abstract] [Full Text]
|
|
|
|
|
|
G. Mastella, M. Rainisio, H.K. Harms, M.E. Hodson, C. Koch, J. Navarro, B. Strandvik, and S.G. McKenzie Allergic bronchopulmonary aspergillosis in cystic fibrosis Eur. Respir. J., May 1, 2001; 17(5): 1052 - 1053. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Stevens, H. J. Schwartz, J. Y. Lee, B. L. Moskovitz, D. C. Jerome, A. Catanzaro, D. M. Bamberger, A. J. Weinmann, C. U. Tuazon, M. A. Judson, et al. A Randomized Trial of Itraconazole in Allergic Bronchopulmonary Aspergillosis N. Engl. J. Med., March 16, 2000; 342(11): 756 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Salez, A. Brichet, S. Desurmont, J.-M. Grosbois, B. Wallaert, and A.-B. Tonnel Effects of Itraconazole Therapy in Allergic Bronchopulmonary Aspergillosis* Chest, December 1, 1999; 116(6): 1665 - 1668. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
